IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

MAERTENS et al.

Serial No. 09/638.693

Filed: August 15, 2000

For: NEW SEQUENCES OF HEPATITIS C VIRUS

GENOTYPES AND THEIR USE AS THERAPEUTIC AND

DIAGNOSTIC AGENTS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 February 1, 2005

Atty. Ref.:

Examiner:

Group:

2551-114

Martinell

1631

Sir:

INFORMATION DISCLOSURE STATEMENT

冈 PTO-1449 Pursuant to 37 CFR 1.97(b) [within 3 months of filing or prior to 1st Office Action on the merits] N/C 2.(a) Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] N/C 2 .(b) Fee Payment Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] \$180.00 3. Pursuant to 37 CFR 1.97(d) [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment] \$180.00



The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

\boxtimes	4.	A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.							
his p	aper	is sub	omitted in accordance with:						
\boxtimes	5.	37 (CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]						
	6.	37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and							
		a)	The required Statement made in item 8 below; or						
		b)	The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.						
	7.	37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and							
		a)	The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and						
		b)	The required Statement is stated in item 8 below.						
	8.	Statement under 37 CFR 1.97(e)							
		a)	The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or						
		b)	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.						



9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted, NIXON & VANDERHYE P.C.

By:

3 J. Sadofi

Reg. No. 36,663

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

INFORMATION DISCLOSURE CITATION

2551-114 **APPLICANT**





SERIAL NO.

09/638,693

MAERTENS et al.

(Use several sheets if necessary) FILING DATE GROUP

1631

			Augus	st 15, 2000 1	631							
			U.S	. PATENT DOCUMENTS								
XAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME :	CLASS	SUBCLASS	IF APPR					
	114	6,548,244 B2	04/15/03	Maertens et al	435	5	07/06	/200				
	120	5,846,704	12/08/98	Maertens et al	435	5	07/18	/1994				
	150	5,514,539	05/07/96	Bukh et al	435	5	06/29	/199				
	151	5,882,852	03/16/99	Bukh et al	435	5	09/15	/199				
	152	5,372,928	12/13/94	Miyamura et al	435	5	02/24	/199				
	22	5,530,671	6/1996	Houghton								
	342	6,762,024	7/2004	Maertens								
	l	<u> </u>		IGN PATENT DOCUMENTS	•	·						
							TRANSLATIO					
		DOCUMENT	DATE	COUNTRY	CLASS -	SUBCLASS	YES	NO				
	154	0 463 848 A2	01/02/92	Europe								
	153	2 239 245 A	06/26/91	United Kingdom			<u> </u>					
		OTHER DOCUM	MENTS (inc	cluding Author, Title, Date, P	ertinent pa	ages, etc.	.)					
	343	Co, PNAS 88(7) 286										
' 	149	49 Majzoub et al, Journal of Biological Chemistry, 1983, Vol. 258:14061-14064										
	1 1											
<u> </u>	+ +					-						
<u> </u>	+											
-	+ -											
xaminer				Date Considered	T							

Form PTO-FB-A820 (Also PTO-1449)